Terui Ken, Kageyama Kazunori, Nigawara Takeshi, Moriyama Takako, Sakihara Satoru, Takayasu Shinobu, Tsushima Yuko, Watanki Yutaka, Yamagata Satoshi, Sugiyama Aya, Murasawa Shingo, Nakada Yuki, Suda Toshihiro, Daimon Makoto
Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan
Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Japan.
J Renin Angiotensin Aldosterone Syst. 2016 Mar 23;17(1):1470320315625703. doi: 10.1177/1470320315625703. Print 2016 Jan-Mar.
The purpose of this study was to investigate the diagnostic power of the adrenocorticotropin (ACTH) stimulation test in patients with primary aldosteronism (PA) and those with aldosterone-producing adenoma (APA).
This study was based on a retrospective database analysis.
We assessed 158 hypertensive patients with a high plasma aldosterone-to-renin ratio (ARR) including 97 with at least one positive confirmatory test result who did not undergo surgery and comprised a "possible PA" group, 19 with negative results in all tests who were the "non-PA" group, and 41 diagnosed with APA following surgery who were the APA group. The "confirmed PA group" included APA patients and patients from the possible PA group showing both high ARR and hypokalemia. One case was diagnosed as a metastasis.
Receiver-operating characteristic (ROC) analysis showed that the diagnostic accuracy of ACTH test was not very effective in differentiating between APA patients and possible PA and non-PA patients. The optimal cut-off value of maximal plasma aldosterone concentration for differentiating between patient in the confirmed PA group and other patients showed moderate accuracy.
The ACTH test may not be useful as a screening or confirmatory test, but the test may be useful for differentiating between patients with confirmed PA and the rest of the cohort. The positive finding of the ACTH test may at least support a higher likelihood of lateralizing on adrenal venous sampling.
本研究旨在探讨促肾上腺皮质激素(ACTH)刺激试验对原发性醛固酮增多症(PA)患者及醛固酮瘤(APA)患者的诊断价值。
本研究基于回顾性数据库分析。
我们评估了158例血浆醛固酮与肾素比值(ARR)升高的高血压患者,其中97例至少有一项确诊试验结果为阳性且未接受手术,组成“可能PA”组;19例所有试验结果均为阴性,为“非PA”组;41例术后诊断为APA,为APA组。“确诊PA组”包括APA患者以及来自可能PA组且ARR高和低钾血症的患者。1例被诊断为转移瘤。
受试者操作特征(ROC)分析表明,ACTH试验在区分APA患者与可能PA和非PA患者方面的诊断准确性不是很高。区分确诊PA组患者与其他患者的最大血浆醛固酮浓度的最佳截断值显示出中等准确性。
ACTH试验可能不适用于筛查或确诊试验,但该试验可能有助于区分确诊PA患者与其他队列患者。ACTH试验的阳性结果至少可能支持肾上腺静脉采血定位的较高可能性。